English
Chinese (Simplified)
French
Portuguese
Spanish
German
Forward
Print
Comment
Molecular Imaging Homepage
TeamBest companies to acquire ABT Molecular Imaging, launch Best ABT Bringing greater expertise to smaller cyclotron technology
Dr. Bernhard Sixt Edinburgh Molecular Imaging appoints as new Chief Executive Officer
Missouri reactor becomes sole US domestic source of I-131 A vital radioisotope in the fight against thyroid cancer and hyperthyroidism
Cardinal Health to distribute IRE ELiT's 68-Ga generators Aiming to alleviate access shortages with Galli Eo generators
Zionexa partners with Columbia PET Center on development of EstroTep Identifies estrogen receptor status to diagnose metastatic breast cancer
Canada to build medical isotope research and development center Will act as a regional source for isotopes, including Tc-99m
SNMMI warns providers to prep for expected shortage of Mo-99 Due to shutdowns of two reactors
RefleXion demonstrates BgRT PET system at ASTRO Treat all stages of cancer, including metastatic
GE to provide training to at least 140 Kenyan radiographers Partnering with Society of Radiography in Kenya
NorthStar, Shine in line for federal funding Bringing $20 million in additional funding to domestic moly-99 in the US
New technologies to help expand PET/CT imaging in emerging markets
PET/CT is an important modality today in oncology, and there has been a robust growth in the installation of cyclotrons and PET/CT scanners in developed countries, where the strategy has been to establish centralized radiopharmacies to supply 18FDG to facilities within a distribution grid.
Establishing a conventional cyclotron can be complex due to the significant infrastructure and equipment costs, and the demand for specialized support.
Servicing GE Nuclear Medicine equipment with OEM trained engineers
We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED
In emerging markets, this centralized distribution model is much more difficult due to economic challenges and transportation logistics. A trend towards smaller and simpler solutions has progressed, with companies offering “table top” cyclotrons with compact and automated radiochemistry units This decentralized strategy enables the users to produce on-demand doses 18FDG and other tracers using an automated and user-friendly technology, providing availability at an affordable cost to these developing countries.
One example is the BG-75 “Dose on Demand” Biomarker Generator from ABT Molecular Imaging. The company offers a 7.5Mev cyclotron with simplified single or small batch 18FDG production, and automated quality control. The solution has made it economically feasible to implement in-house radiopharmaceutical production. For example, Fundacion Valle de Lili Hospital in Cali, Columbia, was having FDG transported via airlines from a city >400 km away at considerable cost. By implementing the first Biomarker Generator System in Colombia, they were able to reduce their 18FDG costs, and expand their scheduling.
Another example can be found in the largest island in Southeast Asia. With a population of 18 million citizens, Borneo had no access to PET/CT due to lack of access to 18FDG. Borneo Medical Center used an existing 35 m2 space in their hospital to install the Biomarker Generator System, and is now the first provider to offer PET/CT.
While having economical, on-demand access to 18FDG is most important for emerging markets to initiate PET/CT, the capability to produce other more specific tracers is equally important. German Oncology Center, who also installed the first Biomarker Generator and PET/CT on the island of Cyprus, is a highly specialized, private oncology center. They not only produce 18FDG, but also other important tracers such as PSMA for prostate imaging, and FET for brain tumor imaging.
The global growth of PET/CT may well be accelerated by this decentralized approach, where hospitals and health care providers can produce on-demand doses of PET radiopharmaceuticals by installing this type of compact, automated, and user-friendly system.
About the author: Rick Rippin is the sales director for ABT Molecular Imaging
You Must Be Logged In To Post A CommentRegisterRegistration is Free and Easy. Enjoy the benefits of The World's Leading New & Used Medical Equipment Marketplace. Register Now! |
|
